|
業務類別
|
Biotechnology |
|
業務概覽
|
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Itspipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program. |
| 公司地址
| 3115 Merryfield Row, Suite 300, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 858 465-6511 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.erasca.com |
| 員工數量
| 103 |
| Dr. Shannon R. Morris, M.D.,PhD |
Chief Medical Officer |
美元 486.50K |
29/04/2025 |
| Dr. David M. Chacko, M.D. |
Chief Financial Officer, Principal Accounting Officer and Chief Business Officer |
美元 492.10K |
12/03/2026 |
| Dr. Jonathan E. Lim,M.D. |
Chairman of the Board and Chief Executive Officer |
美元 644.60K |
12/03/2026 |
| Mr. Ebun S. Garner |
General Counsel and Corporate Secretary |
-- |
29/04/2025 |
|
|
| Dr. James A. Bristol, PhD |
Lead Independent Director |
12/03/2026 |
| Dr. Julie Hambleton, M.D. |
Independent Director |
12/03/2026 |
| Dr. Pratik S. Multani, M.D. |
Independent Director |
12/03/2026 |
| Dr. Michael D. Varney, PhD |
Director and Chair of Research and Development |
12/03/2026 |
| Dr. Jonathan E. Lim,M.D. |
Chairman of the Board and Chief Executive Officer |
12/03/2026 |
| Ms. Jean I. Liu, J.D. |
Independent Director |
12/03/2026 |
| Mr. Alexander W. Casdin |
Independent Director |
12/03/2026 |
| Dr. Valerie Harding Start, PhD |
Independent Director |
12/03/2026 |
|
|
|
|
